SPC515
Lazertíníb á öllum formum þess sem eru vernduð af grunneinkaleyfinu / Lazertinib in all its forms protected by the basic patent
Status:
UmsóknApplication date:
2.6.2025Application published:
1.7.2025
Medicine name:
LazcluzeMedicine for children:
No
Timeline
Today
2.6.2025Application
1.7.2025Publication
Marketing license
Foreign authorization number:
EU/1/24/1886Date:
20.1.2025
Owner
Name:
Yuhan CorporationAddress:
74 Noryangjin-ro Dongjak-gu, Seoul KR
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP3207035